Nuvectis Pharma (NVCT) Cash & Equivalents (2021 - 2026)

Nuvectis Pharma has reported Cash & Equivalents for 6 years, with the latest figure at $25.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 16.05% year-over-year to $25.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.1 million (down 16.05% YoY) and the FY2025 annual result came in at $31.6 million, up 70.69% from the prior year.
• Cash & Equivalents declined to $25.1 million in Q1 2026 per NVCT's latest filing, from $31.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $35.4 million in Q3 2025 and troughed at $13.6 million in Q2 2022.
• A 5-year average of $22.3 million and a median of $20.8 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents declined 26.36% in 2024, then soared 106.43% in 2025.
• Over 5 years, Cash & Equivalents stood at $23.6 million in 2022, then slipped by 18.96% to $19.1 million in 2023, then decreased by 3.1% to $18.5 million in 2024, then jumped by 70.69% to $31.6 million in 2025, then retreated by 20.65% to $25.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $25.1 million, $31.6 million, and $35.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.